Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About PLIANT THERAPEUTICS, INC.
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 158 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The firm has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. The company has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. The company has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The firm has a preclinical program, PLN-101325, targeting muscular dystrophies.
Industry: Pharmaceutical Preparations Peers: Aclaris Therapeutics, Inc. Amphastar Pharmaceuticals, Inc. BELITE BIO, INC RELMADA THERAPEUTICS, INC. CinCor Pharma, Inc. JOHNSON & JOHNSON NGM BIOPHARMACEUTICALS INC